Weiru Hong

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Walter Fiedler, Hubert Serve, Hartmut Döhner et al. · Blood · 2005 · 492 citations

Medicine, Oncology, Pharmacology +13

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Lesley Murray, Tinya J. Abrams, Kelly R. Long et al. · Clinical & Experimental Metastasis · 2003 · 304 citations

Medicine, Oncology, Pharmacology +14

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Francis J. Giles, Alison Stopeck, Lewis R. Silverman et al. · Blood · 2003 · 198 citations · Full text

Medicine, Oncology, Pharmacology +14

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

Anne-Marie O’Farrell, Helene A. Yuen, Beverly D. Smolich et al. · Leukemia Research · 2004 · 76 citations

Medicine, Oncology, Pharmacology +14